Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+T-cell responses and immune memory

Intermittent Metronomic Drug Schedule Is Essential for Activating Antitumor Innate Immunity and Tumor Xenograft Regression

(2015) Chong-Sheng Chen et al.   NEOPLASIA

Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model

(2014) Junjie Wu et al.   CANCER LETTERS

Enhanced suppressor function of TIM-3+FoxP3+regulatory T cells

(2014) Anne-Sophie Gautron et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Tumor-Associated Macrophages: From Mechanisms to Therapy

(2014) Roy Noy et al.   IMMUNITY

Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients

(2014) Jennifer E. Adair et al.   JOURNAL OF CLINICAL INVESTIGATION

Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication

(2014) Sofie Denies et al.   JOURNAL OF CONTROLLED RELEASE

Increased Antitumor Effects Using IL-2 with Anti–TGF-β Reveals Competition between Mouse NK and CD8 T Cells

(2014) Maite Alvarez et al.   JOURNAL OF IMMUNOLOGY

Immune Memory–Boosting Dose of Rapamycin Impairs Macrophage Vesicle Acidification and Curtails Glycolysis in Effector CD8 Cells, Impairing Defense against Acute Infections

(2014) Emily L. Goldberg et al.   JOURNAL OF IMMUNOLOGY

Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2

(2014) Joshua C Doloff et al.   Molecular Cancer

Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity

(2014) Andriy Marusyk et al.   NATURE

Metronomics: towards personalized chemotherapy?

(2014) Nicolas André et al.   Nature Reviews Clinical Oncology

Trial Watch

(2014) Erika Vacchelli et al.   OncoImmunology

Chemoimmunotherapy: reengineering tumor immunity

(2013) Gang Chen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

(2013) L Bracci et al.   CELL DEATH AND DIFFERENTIATION

Metronomic therapy: Chemotherapy revisited

(2013) K Prabhash et al.   INDIAN JOURNAL OF CANCER

Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy

(2013) Melissa G. Lechner et al.   JOURNAL OF IMMUNOTHERAPY

The causes and consequences of genetic heterogeneity in cancer evolution

(2013) Rebecca A. Burrell et al.   NATURE

Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine

(2012) Shiwen Peng et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo

(2012) Miki Tongu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis

(2012) Li Jia et al.   CANCER LETTERS

VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity-Induced Tumor Regression

(2012) J. C. Doloff et al.   CANCER RESEARCH

Role of Chemokines and Chemokine Receptors in Shaping the Effector Phase of the Antitumor Immune Response

(2012) K. Franciszkiewicz et al.   CANCER RESEARCH

Dose-Dense Chemotherapy Improves Mechanisms of Antitumor Immune Response

(2012) C.-L. Chang et al.   CANCER RESEARCH

Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects

(2012) Zhi-Chun Ding et al.   Clinical & Developmental Immunology

CSF-1 signaling in macrophages: pleiotrophy through phosphotyrosine-based signaling pathways

(2012) Kellie A. Mouchemore et al.   CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

Tumor Necrosis Factor-α Signaling in Macrophages

(2012) Narayanan Parameswaran et al.   CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

Inflammatory Monocytes Activate Memory CD8+ T and Innate NK Lymphocytes Independent of Cognate Antigen during Microbial Pathogen Invasion

(2012) Saïdi M'Homa Soudja et al.   IMMUNITY

Cyclophosphamide Promotes Chronic Inflammation–Dependent Immunosuppression and Prevents Antitumor Response in Melanoma

(2012) Alexandra Sevko et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The Efficacy Versus Toxicity Profile of Combination Virotherapy and TLR Immunotherapy Highlights the Danger of Administering TLR Agonists to Oncolytic Virus-treated Mice

(2012) Diana M Rommelfanger et al.   MOLECULAR THERAPY

A restricted cell population propagates glioblastoma growth after chemotherapy

(2012) Jian Chen et al.   NATURE

Regulatory T-Cells: Diverse Phenotypes Integral to Immune Homeostasis and Suppression

(2012) Richard A. Peterson   TOXICOLOGIC PATHOLOGY

Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation

(2012) Apostolis Stathopoulos et al.   OncoImmunology

Tumor Immunology: Basic and Clinical Advances

(2011) P. L. Beatty et al.   CANCER RESEARCH

Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide

(2011) F. Moschella et al.   CANCER RESEARCH

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

(2011) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design

(2011) Antonella Sistigu et al.   Seminars in Immunopathology

Chemoimmunotherapy

(2010) Leisha A. Emens   CANCER JOURNAL

Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis

(2010) G. Schiavoni et al.   CANCER RESEARCH

Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment

(2010) Thomas F Gajewski et al.   CURRENT OPINION IN IMMUNOLOGY

Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape

(2010) Robert L. Ferris et al.   JOURNAL OF CLINICAL ONCOLOGY

Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress

(2010) I Martins et al.   ONCOGENE

The Immune Response and the Therapeutic Effect of Metronomic Chemotherapy With Cyclophosphamide

(2010) Viviana R. Rozados et al.   ONCOLOGY RESEARCH

The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications

(2010) Anna Maria Di Giacomo et al.   SEMINARS IN ONCOLOGY

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

(2009) Claire Banissi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model

(2009) S. Wada et al.   CANCER RESEARCH

The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade

(2009) Lana E. Kandalaft et al.   GYNECOLOGIC ONCOLOGY

Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression

(2009) Ethan M. Shevach   IMMUNITY

Current immunotherapy for solid tumors

(2009) Lisbeth Barkholt et al.   Immunotherapy

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Cyclophosphamide and cancer: golden anniversary

(2009) Ashkan Emadi et al.   Nature Reviews Clinical Oncology

Immunogenic death of colon cancer cells treated with oxaliplatin

(2009) A Tesniere et al.   ONCOGENE

The anticancer immune response: indispensable for therapeutic success?

(2008) Laurence Zitvogel et al.   JOURNAL OF CLINICAL INVESTIGATION